Evidence map›Paper›PMID 34222647›Full record

ArticlePleura and peritoneum2021

Predictors of morbidity and mortality in patients submitted to cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for ovarian carcinomatosis: a multicenter study.

Antonio Macrì, Fabio Accarpio, Vincenzo Arcoraci, Francesco Casella, Franco De Cian, Pierandrea De Iaco, Elena Orsenigo, Franco Roviello, Giovanni Scambia, Edoardo Saladino and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pleura and peritoneum, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 1 country.

Antonio MacrìDepartment of Human Pathology, University of Messina, Via Consolare Valeria, 98125, Messina, Italy.
Fabio AccarpioCytoreductive Surgery and HIPEC Unit - Department of Surgery "Pietro Valdoni", University "Sapienza" of Rome, Rome, Italy.
Vincenzo ArcoraciDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Francesco Casella1st Department of General Surgery, University of Verona, Verona, Italy.
Franco De CianDepartment of Surgery, University of Genoa, Genoa, Italy.
Pierandrea De IacoDepartment of Obstetrics and Gynecology, St. Orsola Hospital, University of Bologna, Bologna, Italy.
Elena OrsenigoDepartment of Surgery, San Raffaele Scientific Institute, Milan, Italy.
Franco RovielloDepartment of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
Giovanni ScambiaDepartment of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy.
Edoardo SaladinoPapardo Hospital, Messina, Italy.
Marica GalatiEmergency Surgery Unit, University Hospital, Messina, Italy.
University of Messina · ITAzienda Ospedaliera Ospedali Riuniti Papardo Piemonte · ITOspedale San Pietro Fatebenefratelli · ITSan Raffaele University of Rome · ITUniversità Cattolica del Sacro Cuore · ITUniversity of Bologna · ITUniversity of Genoa · ITUniversity of Siena · ITUniversity of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe aim of this retrospective study is to assess the incidence of morbidity and mortality related to cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) and to evaluate their predictors, in patients with peritoneal metastasis of ovarian origin.

methodsA retrospective multicenter study was carried out investigating results from eight Italian institutions. A total of 276 patients met inclusion criteria. Predictors of morbidity and mortality were evaluated with univariate and multivariate analysis.

resultsOverall morbidity was 71.4%, and severe complications occurred in 23.9% of the sample; 60-day mortality was 4.3%. According to univariate logistic regression models, grade 3-4 morbidity was related to Peritoneal Cancer Index (PCI) (OR 1.06; 95% CI 1.02-1.09; p<0.001), number of intraoperative blood transfusions (OR 1.21; 95% CI 1.10-1.34; p<0.001), Completeness of Cytoreduction (CC) score (OR 1.68; 95% CI 1.16-2.44; p=0.006) and number of anastomoses (OR 1.32; 95% CI 1.00-1.73; p=0.046). However, at the multivariate logistic regression analysis, only the number of intraoperative blood transfusions (OR 1.17; 95% CI 1.5-1.30; p=0.004) and PCI (OR 1.04; 95% CI 1.01-1.08; p=0.010) resulted as key predictors of severe morbidity. Furthermore, using multivariate logistic regression model, ECOG score (OR 2.45; 95% CI 1.21-4.93; p=0.012) and the number of severe complications (OR 2.16; 95% CI 1.03-4.52; p=0.042) were recorded as predictors of exitus within 60 days.

conclusionsThe combination of CRS and HIPEC for treating peritoneal metastasis of ovarian origin has acceptable morbidity and mortality and, therefore, it can be considered as an option in selected patients.

Indexed as

hyperthermic intraperitoneal chemotherapy (HIPEC)morbiditymortalityovarian carcinomatosispredictor

Identifiers

PMID34222647
PMCPMC8223801
OpenAlexW3134817517

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.